Gout: thoughts about a treat-to-target programme.
Gout is a rheumatic disease resulting from deposition of uric acid crystals in tissues and fluids within the body. The pathogenesis involves underexcretion or overproduction of uric acid, a biproduct of metabolism of purines, resulting in a metabolic disorder commonly known as hyperuricaemia, has a relatively high prevalence in the population (0.5-1%, similar to rheumatoid arthritis). Patients with hyperuricaemia are at risk to develop acute gouty attacks which may be severely painful. The attacks tend to occur episodically over a few days up to a week or two, but gout may later become chronic. Different aims of therapy and management are well suited as targets of treatment, including reduction of purine intake, increased of excretion of uric acid, mobilisation of urate pools within the body, and reduction of acute and chronic inflammation through anti-inflammatory medications.
Rheumazentrum Ruhrgebiet, Herne, Germany. j.braun@rheumazentrum-ruhrgebiet.de
Juergen
J
Braun
Josef S
JS
Smolen
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D004035:Diet Therapy; D019468:Disease Management; D006073:Gout / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D033461:Hyperuricemia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D010347:Patient Care Planning
D000893:Anti-Inflammatory Agents; D006074:Gout Suppressants